欧洲视角解读2015年美国甲状腺协会成人甲状腺结节与分化型甲状腺癌管理指南
本文为欧洲核医学协会组织的研讨会立场文件,比较欧洲与ATA 2015指南在甲状腺结节术前评估、手术、放射碘治疗等方面的观点差异。欧洲专家建议对约三分之一的ATA 2015推荐进行修改,分歧主要涉及≤4 cm肿瘤的腺叶切除、术后放射碘治疗的应用范围、rhTSH的使用及剂量学方法等。
要点
- 欧洲专家对ATA 2015约三分之一的推荐提出修改建议。
- 欧洲专家比ATA 2015更支持术后放射碘治疗及rhTSH的广泛使用。
- 欧洲专家反对对≤4 cm肿瘤广泛采用腺叶切除,理由包括无法行放射碘治疗等。
核心结论
- 欧洲专家建议对ATA 2015约三分之一的推荐进行修改。
- 欧洲与ATA 2015视角的差异可激发文献分析和原始研究以解决分歧并改善患者结局。
研究设计与样本
- 欧洲核医学协会组织的受邀研讨会,17名欧洲甲状腺专家、4名ATA指南工作组成员及200名国际专家参与。
- 讨论形成本立场文件,对比欧洲与ATA 2015在关键问题上的观点。
主要发现
- 欧洲专家反对广泛采用腺叶切除,理由包括无法行放射碘治疗、可能需补行甲状腺全切、常无法避免长期甲状腺激素替代及支持证据有限。
- 欧洲专家比ATA 2015更支持术后放射碘治疗,理由包括与良好患者结局相关、毒性一般有限及缺乏高质量证据支持省略放射碘治疗。
- 欧洲专家比ATA 2015在更多情况下支持使用重组人促甲状腺激素,理由为避免甲减相关疾病和生活质量损害且不损害肿瘤学结局。
- 欧洲专家基于临床证据和理论优势,主张对晚期分化型甲状腺癌采用剂量学方法而非固定活度方法进行放射碘治疗。
- 欧洲专家指出ATA 2015风险分层系统所需信息在日常实践中有时不可获得。
关键数值与推荐
- ATA 2015对原发肿瘤≤4 cm允许行腺叶切除,欧洲专家对此持反对意见。
- 欧洲专家主张对晚期分化型甲状腺癌采用剂量学方法而非固定活度方法进行放射碘治疗。
- ATA 2015关于放射碘难治性分化型甲状腺癌的推荐应考虑对同时存在放射碘敏感病灶的患者行放射碘治疗的潜在姑息获益。
临床怎么用
- 临床决策时应认识到欧洲与ATA 2015在腺叶切除、术后放射碘治疗及rhTSH使用上存在观点差异。
- 对晚期分化型甲状腺癌可考虑剂量学方法指导放射碘治疗。
- 对放射碘难治性但存在放射碘敏感病灶的患者,可考虑放射碘治疗的潜在姑息获益。
局限性
- 本文为研讨会立场文件,非系统评价或原始研究。
- 欧洲专家观点基于欧洲的流行病学、技术方法、实践组织和医疗法律背景,可能不完全适用于其他地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Thyroid Association (ATA) management guidelines for patients with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 ("ATA 2015"). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. SUMMARY: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, four ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed the preoperative assessment of thyroid nodules, surgery and the role of pathology, radioiodine (RAI) therapy (RAIT), the assessment of initial therapy and dynamic risk stratification, and the treatment of persistent disease, recurrences, and advanced thyroid cancer. The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to the permissiveness of ATA 2015 regarding lobectomy for primary tumors ≤4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015's guidance regarding RAIT. European panelists favored wider use of postoperative RAIT than does ATA 2015. Rationales included the modality's association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin (rhTSH) in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinical evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk-stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding RAI-refractory DTC should consider potential palliative benefits of RAIT in patients who also have RAI-susceptible lesions. CONCLUSIONS: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of the literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.
引用
- Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019. PMID: 30484394. doi:10.1089/thy.2017.0129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。